{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.1","upperLimit":"49.9","value":"39.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"}],"units":"Participants"}],"description":"6-months PFS rate assessed by the investigators according to Criteria for Response Assessment of Lymphoma: Lugano 2014 Classification","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received sugemalimab (CS1001) 1200 mg intravenously every 3 weeks (Q3W)","id":"OG000","title":"R/R ENKTL"}],"paramType":"NUMBER","populationDescription":"one patient was excluded from the efficacy analysis set because the patient was not confirmed as ENKTL by central pathology.","reportingStatus":"POSTED","timeFrame":"6 months","title":"6-months Progression-free Survival (PFS) Rate Assessed by Investigators","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Percentage of participants"}